Tiotropium bromide - Glenmark Pharmaceuticals

Drug Profile

Tiotropium bromide - Glenmark Pharmaceuticals

Alternative Names: GSP 304

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Mar 2017 Preclinical trials in Chronic obstructive pulmonary disease in India (PO)
  • 07 Mar 2017 The US FDA approves IND application for tiotropium bromide (GSP 304) in Chronic obstructive pulmonary disease
  • 07 Mar 2017 Glenmark Pharmaceuticals plans a phase II trial for Chronic obstructive pulmonary disease in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top